Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05220410 · ClinicalTrials.gov registry record · Phase 2
The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal Ideation
A Phase 2 study, sponsored by Sheppard Pratt Health System.
- Completed
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT05220410 is a Phase 2 study that has completed, run by Sheppard Pratt Health System. The registered enrollment target is 20 participants.
The verdict
NCT05220410, a Phase 2 study, has completed, sponsored by Sheppard Pratt Health System.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
This study aims to explore the safety and tolerability of a single dose of psilocybin (25mg) administered under supportive conditions to adult participants with TRD and chronic suicidal ideation
Interventions
- DRUG Psilocybin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2022-03-28 |
| Est. Completion | 2025-05-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05220410
The ClinicalTrials.gov registry entry for NCT05220410 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sheppard Pratt Health System, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Psilocybin is the first listed.
NCT05220410 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05220410 about?
NCT05220410 is a clinical study titled "The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal Ideation". This study aims to explore the safety and tolerability of a single dose of psilocybin (25mg) administered under supportive conditions to adult participants with TRD and chronic suicidal ideation
What is the current status of trial NCT05220410?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2022-03-28. Estimated completion is 2025-05-12.
What interventions are being tested in trial NCT05220410?
The interventions under investigation include: Psilocybin (DRUG).
Who is sponsoring clinical trial NCT05220410?
This trial is sponsored by Sheppard Pratt Health System, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.